Efficacy and Cytokine Modulating Effects of Tacrolimus in Systemic Lupus Erythematosus: A Review

被引：38

作者：

Yoon, Kam Hon ^{[1
]}

机构：

[1] El Shaddai Arthrit & Rheumatism Specialist Med Ct, Singapore 322102, Singapore

来源：

JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY | 2010年

关键词：

TOPICAL TACROLIMUS; DISEASE-ACTIVITY; NEPHRITIS; FK506; THERAPY; INTERLEUKIN-10; LYMPHOCYTES; INHIBITION; RESISTANT;

D O I：

10.1155/2010/686480

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease with involvement of both B cells and cytotoxic T lymphocytes and several cytokines aberrations. Standard therapy for SLE has its limitations. Tacrolimus, a novel calcineurin inhibitor with potent immunosuppressive effects, has been shown in the recent years to be effective in SLE therapy. This paper serves to collate the experimental and clinical data on the efficacy of tacrolimus in the treatment of SLE and lupus nephritis. Tacrolimus as a key component of multitarget therapy in SLE is also discussed. The immunocytokine modulatory effects of tacrolimus are also reviewed with reference to SLE. It can be concluded that tacrolimus has an established role in the management of SLE.

引用

页数：4

共 37 条

[11]

Heidt S, 2009, J TRANSLATIONAL IMMU, V159, P199

[12] Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production [J].

Jiang, HS ;

Wynn, C ;

Pan, F ;

Ebbs, A ;

Erickson, LM ;

Kobayashi, M .

TRANSPLANTATION, 2002, 73 (11) :1808-1817

[13] Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus [J].

Kanekura, T ;

Yoshii, N ;

Terasaki, K ;

Miyoshi, H ;

Kanzaki, T .

BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (02) :353-356

[14] New pieces to the SLE cytokine puzzle [J].

Kirou, KA ;

Crow, MK .

CLINICAL IMMUNOLOGY, 1999, 91 (01) :1-5

[15]

LAU CS, 2004, APLAR J RHEUMATOLOGY, V7, P83

[16] The role of interleukin-10 in systemic lupus erythematosus [J].

Llorente, L ;

Richaud-Patin, Y .

JOURNAL OF AUTOIMMUNITY, 2003, 20 (04) :287-289

[17] Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study [J].

Madan, V. ;

August, P. J. ;

Chalmers, R. J. G. .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2010, 35 (01) :27-30

[18]

Magari K, 2003, J RHEUMATOL, V30, P2193

[19]

Maruyama M, 2006, CLIN NEPHROL, V65, P276

[20] Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil [J].

Millán, O ;

Brunet, M ;

Campistol, JM ;

Faura, A ;

Rojo, I ;

Vidal, E ;

Jiménez, O ;

Vives, J ;

Oppenheimer, F ;

Martorell, J .

CLINICAL CHEMISTRY, 2003, 49 (11) :1891-1899

← 1 2 3 4 →